Ann: Improving results from stage 1 of TACTI-002 ph II trial, page-5

Well these two paragraphs say it all really.

Principal investigator, Dr Martin Forster, University College London Hospital, said: “We are very encouraged by the results in this patient group with resistant late stage Head & Neck Cancers where the likelihood of response to other treatments is small. The durability of responses and the two patients with a complete response are extremely promising signals and this combination should be further investigated.”

Immutep CSO and CMO, Dr Frederic Triebel said: “The combination of efti and pembrolizumab is reporting encouraging progression free survival in patients with HNSCC and NSCLC, improving on the results from separate historical trials. For example, in comparable studies, HNSCC patients receiving
1,2 pembrolizumab monotherapy had a PFS of 2.1 months, or 2.3 months if given chemotherapy . This
compares to a PFS of 4.3 months in HNSCC patients from the TACTI-002 trial, thus far. To have these very good and durable responses in both groups and without the use of chemotherapy is highly encouraging for efti.”

These results combined with the AIPAC trial results should see our share price finally start to rise.....finally .....finally , we are perhaps on our way. GLTA